Literature DB >> 27153851

Usefulness of an ad hoc questionnaire (Acro-CQ) for the systematic assessment of acromegaly comorbidities at diagnosis and their management at follow-up.

F Guaraldi1, D Gori2, G Beccuti3, N Prencipe3, R Giordano3,4, Y Mints5, V S Di Giacomo3, A Berton3, M Lorente3, V Gasco3, E Ghigo3, R Salvatori5, S Grottoli3.   

Abstract

PURPOSE: To determine the validity of a self-administered questionnaire (Acro-CQ) developed to systematically assess the presence, type and time of onset of acromegaly comorbidities.
METHODS: This is a cross-sectional study; 105 acromegaly patients and 147 controls with other types of pituitary adenoma, referred to a specialized Italian Center, autonomously compiled Acro-CQ in an outpatient clinical setting. To test its reliability in a different setting, Acro-CQ was administered via mail to 78 patients with acromegaly and 100 with other pituitary adenomas, referred to a specialized US Center. Data obtained from questionnaires in both settings were compared with medical records (gold standard).
RESULTS: Demographics of patients and controls from both countries were similar. In both settings, >95 % of the questionnaires were completely filled; only one item was missed in the others. Concordance with medical record was excellent (k > 0.85) for most of the items, independently from the way of administration, patient age, gender and nationality, pituitary adenoma type and disease activity.
CONCLUSIONS: Acro-CQ is an inexpensive, highly accepted from patients and reliable tool recommended to expedite systematic collection of relevant clinical data in acromegaly at diagnosis, to be replicated at follow-ups. This tool may guide a targeted, cost-effective management of complications. Moreover, it could be applied to retrieve data for survey studies in both acromegaly and other pituitary adenomas, as information is easily and rapidly accessible for statistical analysis.

Entities:  

Keywords:  Acromegaly; Comorbidities; Complications; Pituitary adenoma; Questionnaire validity

Mesh:

Substances:

Year:  2016        PMID: 27153851     DOI: 10.1007/s40618-016-0476-y

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  23 in total

1.  Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis.

Authors:  Gherardo Mazziotti; Elena Biagioli; Filippo Maffezzoni; Maurizio Spinello; Vincenza Serra; Roberto Maroldi; Irene Floriani; Andrea Giustina
Journal:  J Clin Endocrinol Metab       Date:  2014-11-03       Impact factor: 5.958

2.  ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD).

Authors:  Lars Rydén; Peter J Grant; Stefan D Anker; Christian Berne; Francesco Cosentino; Nicolas Danchin; Christi Deaton; Javier Escaned; Hans-Peter Hammes; Heikki Huikuri; Michel Marre; Nikolaus Marx; Linda Mellbin; Jan Ostergren; Carlo Patrono; Petar Seferovic; Miguel Sousa Uva; Marja-Riita Taskinen; Michal Tendera; Jaakko Tuomilehto; Paul Valensi; Jose Luis Zamorano; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Guy De Backer; Per Anton Sirnes; Eduardo Alegria Ezquerra; Angelo Avogaro; Lina Badimon; Elena Baranova; Helmut Baumgartner; John Betteridge; Antonio Ceriello; Robert Fagard; Christian Funck-Brentano; Dietrich C Gulba; David Hasdai; Arno W Hoes; John K Kjekshus; Juhani Knuuti; Philippe Kolh; Eli Lev; Christian Mueller; Ludwig Neyses; Peter M Nilsson; Joep Perk; Piotr Ponikowski; Zeljko Reiner; Naveed Sattar; Volker Schächinger; André Scheen; Henrik Schirmer; Anna Strömberg; Svetlana Sudzhaeva; Juan Luis Tamargo; Margus Viigimaa; Charalambos Vlachopoulos; Robert G Xuereb
Journal:  Eur Heart J       Date:  2013-08-30       Impact factor: 29.983

Review 3.  A guide for the design and conduct of self-administered surveys of clinicians.

Authors:  Karen E A Burns; Mark Duffett; Michelle E Kho; Maureen O Meade; Neill K J Adhikari; Tasnim Sinuff; Deborah J Cook
Journal:  CMAJ       Date:  2008-07-29       Impact factor: 8.262

4.  Quantifying subtle changes in cardiovascular mechanics in acromegaly: a Doppler myocardial imaging study.

Authors:  R Jurcut; S Găloiu; A Florian; A Vlădaia; O R Ioniţă; M S Amzulescu; I Baciu; B A Popescu; M Coculescu; C Ginghina
Journal:  J Endocrinol Invest       Date:  2014-08-15       Impact factor: 4.256

5.  Acromegaly is associated with an increased prevalence of colonic diverticula: a case-control study.

Authors:  M J E Wassenaar; M Cazemier; N R Biermasz; A M Pereira; F Roelfsema; J W A Smit; D W Hommes; R J F Felt-Bersma; J A Romijn
Journal:  J Clin Endocrinol Metab       Date:  2010-03-09       Impact factor: 5.958

Review 6.  The effect of somatostatin analogs on vitamin D and calcium concentrations in patients with acromegaly.

Authors:  Adnan Ajmal; Arezoo Haghshenas; Shirin Attarian; Maya Barake; Nicholas A Tritos; Anne Klibanski; Karen K Miller; Lisa B Nachtigall
Journal:  Pituitary       Date:  2014-08       Impact factor: 4.107

7.  Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients.

Authors:  R Attanasio; A Mainolfi; F Grimaldi; R Cozzi; M Montini; C Carzaniga; S Grottoli; L Cortesi; M Albizzi; R M Testa; L Fatti; D De Giorgio; C Scaroni; F Cavagnini; P Loli; G Pagani; E Ghigo
Journal:  J Endocrinol Invest       Date:  2008-08       Impact factor: 4.256

Review 8.  2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol.

Authors:  Sidney C Smith; Scott M Grundy
Journal:  J Am Coll Cardiol       Date:  2014-08-12       Impact factor: 24.094

Review 9.  Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly--meta-analysis and systematic review.

Authors:  Kosma Wolinski; Agata Czarnywojtek; Marek Ruchala
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

10.  Do postage stamps versus pre-paid envelopes increase responses to patient mail surveys? A randomised controlled trial.

Authors:  Katrina Lavelle; Chris Todd; Malcolm Campbell
Journal:  BMC Health Serv Res       Date:  2008-05-28       Impact factor: 2.655

View more
  6 in total

1.  Evaluation of depressive mood and cognitive functions in patients with acromegaly under somatostatin analogue therapy.

Authors:  H Alibas; K Uluc; P Kahraman Koytak; M M Uygur; N Tuncer; T Tanridag; D Gogas Yavuz
Journal:  J Endocrinol Invest       Date:  2017-06-28       Impact factor: 4.256

2.  The boxer world heavyweight champion Primo Carnera portrayed by Giacomo Balla.

Authors:  F Trimarchi; S Cannavò
Journal:  J Endocrinol Invest       Date:  2018-01-23       Impact factor: 4.256

3.  Auditory changes in acromegaly.

Authors:  S Tabur; H Korkmaz; E Baysal; E Hatipoglu; I Aytac; E Akarsu
Journal:  J Endocrinol Invest       Date:  2016-12-29       Impact factor: 4.256

4.  Colonic Diverticulosis. Is there a Genetic Component?

Authors:  Ana Maria Miulescu
Journal:  Maedica (Bucur)       Date:  2020-03

5.  Multidisciplinary oral rehabilitation in partially edentulous adult patients with malocclusion: A cross-sectional survey study.

Authors:  Renan Devita; Sérgio Pinho; Josep-Maria Ustrell; Henrique Pretti; Esdras-de Campos França; Ertty Silva; Igor Brum
Journal:  J Clin Exp Dent       Date:  2018-12-01

Review 6.  Questionnaire and tools: clinical powerful instrument in acromegaly diagnosis and management.

Authors:  P Maffei; F Dassie; S Camerini; A Wennberg; M Adriani; B Martin; R Vettor
Journal:  J Endocrinol Invest       Date:  2022-03-23       Impact factor: 5.467

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.